- The company reported continued growth of its SSi Mantra surgical robotic system, with installations reaching 238 as of September 8, 2026, with the installed base now spanning 12 countries, following recent launches in Colombia and Sri Lanka and further international expansion.
- The company said cumulative SSi Mantra procedures reached 14,103, a 79% increase from 7,885 at the end of 2025.
- Pediatric applications continue to expand, including a robotic kidney procedure performed on a 45-day-old infant in India using 5-millimeter instruments.
- SS Innovations reported 188 cumulative robotic telesurgeries as of August 31, alongside long-distance procedures connecting surgeons and patients across countries.
- The company expects FDA review of its 510(k) submission by the end of Q1 2027 and believes EU CE marking for SSi Mantra could be obtained by the end of 2026.
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, is reporting continued growth in the use of its SSi Mantra surgical robotic system, with the company’s installed base and procedure count increasing as it expands into new countries and surgical applications.
In an update issued September 10, the company said 238 SSi Mantra systems were installed as of September 8, up 42% from 168 at the end of 2025. Procedures performed with the system reached 14,103, representing a 79% increase from 7,885 at year-end. The company also said approximately 1,500 physicians have now been trained on SSi Mantra, which has been used in more than 170 different types of surgical procedures (https://ibn.fm/PESjb).
International expansion remains a central component of that growth. On July 29, SS Innovations said Dr. Sudhir Srivastava, its chairman and CEO, launched a robotic cardiac surgery program at La Fundación Cardiovascular de Colombia in Bucaramanga. The program included Colombia’s first Totally Endoscopic Beating-Heart Bypass Surgery performed using SSi Mantra.
Less than a month later, Kings Hospital Colombo installed the first SSi Mantra system in Sri Lanka. The company said the system subsequently supported the country’s first robotic-assisted cardiac surgery and more than 25 additional robotic procedures during its first three weeks of operation.
The Sri Lankan launch followed the company’s earlier expansion into other international markets and brought the global installed base to 12 countries. These deployments are significant for SS Innovations because regulatory approvals and clinical adoption outside its established Indian market are important steps in building a broader commercial footprint. The company is simultaneously pursuing U.S. Food and Drug Administration clearance and European regulatory certification.
SS Innovations expects the FDA to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. The company believes it can obtain European Union CE marking by the end of 2026.
The latest update also highlighted the system’s use in pediatric surgery, where smaller anatomy places particular demands on surgical instruments and robotic control. On August 14, Dr. M. Ramalingam used SSi Mantra with 5-millimeter instrumentation to perform a robotic pyeloplasty on a 45-day-old infant at Hindusthan Hospital in Coimbatore, India. SS Innovations said the procedure was completed successfully and that the infant recovered rapidly. As of August 31, the company reported 258 pediatric robotic surgeries performed with SSi Mantra.
Telesurgery is another area where SS Innovations has accumulated a growing body of experience, although it remains an emerging application rather than the company’s primary commercial revenue driver. On July 29, a team led by Dr. Srivastava performed a robotic sleeve gastrectomy remotely between Colombia and India. The company said the procedure involved more than 13,600 miles, or approximately 22,000 kilometers, of fiber-network distance. The remote procedure connected Hospital Internacional de Colombia in Bucaramanga with Mohak Bariatrics and Robotics in Indore, India.
SS Innovations subsequently reported another telesurgery milestone in India. On August 9, surgeons at the company’s headquarters in Gurugram remotely performed three procedures on patients at Shalby Hospital in Ahmedabad, covering approximately 950 kilometers.
On September 5, SSi Mantra was used for what the company described as the first telesurgery within the Philippines, connecting Pampanga and Cotabato across approximately 1,710 kilometers.
As of August 31, the company said 188 robotic telesurgeries had been completed using SSi Mantra. The technology is also being tested at higher utilization levels. On August 15, a surgical team at Mohak Bariatrics and Robotics used five SSi Mantra systems to complete 50 robotic general-surgery procedures in one day.
SS Innovations has been building its installed base primarily around India, where it has had several years to train surgeons and expand procedure volumes. The company is now seeking to replicate that model internationally.
“Our advanced, cost-effective SSi Mantra surgical robotic system is benefitting lives globally, one patient at a time, from a 45-day old baby needing kidney surgery in India to a cardiac patient in Sri Lanka,” said Dr. Srivastava. “Our progress in democratizing access to state-of-the-art surgical robotic care continues to be reflected in growing SSi Mantra installations, procedures and utilization.”
For more information, visit the company’s website at www.SSInnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN